col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

165 Results       Page 1

Springer Science and Business Media LLC: npj Vaccines
  original article Date Title Authors   All Authors
1 [GO] 2024―Feb―22 No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines Ahmet Yalcinkaya, Marco Cavalli, Axel Cederholm, Maribel Aranda-Guillén, Anish Behere, Hedvig Mildner, et al. (+11)
2 [GO] 2024―Feb―21 Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine David G. Alleva, Eline A. Feitsma, Yester F. Janssen, Hendrikus H. Boersma, Thomas M. Lancaster, Thillainaygam Sathiyaseelan, et al. (+17)
3 [GO] 2024―Feb―20 Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection Fan Zhou, Juha Vahokoski, Siri Øyen, Marianne Sævik, Hanne Høyland, Helene H. Sandnes, et al. (+6)
4 [GO] 2024―Feb―05 SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition Claudia Fischer, Edith Willscher, Lisa Paschold, Cornelia Gottschick, Bianca Klee, Sophie Diexer, et al. (+12)
5 [GO] 2024―Jan―30 Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis Pedro Martínez-Fleta, Esther F. Vicente-Rabaneda, Ana Triguero-Martínez, Emilia Roy-Vallejo, Miren Uriarte-Ecenarro, Francisco Gutiérrez-Rodríguez, et al. (+18)
6 [GO] 2024―Jan―26 MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans Leonie Mayer, Leonie M. Weskamm, Anahita Fathi, Maya Kono, Jasmin Heidepriem, Verena Krähling, et al. (+12)
7 [GO] 2024―Jan―20 Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2 Klara Lenart, Rodrigo Arcoverde Cerveira, Fredrika Hellgren, Sebastian Ols, Daniel J. Sheward, Changil Kim, et al. (+18)
8 [GO] 2024―Jan―05 Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike Wonyeong Jung, Dansu Yuan, Benjamin Kellman, Isabela Garrido da Silva Gonzalez, Ralf Clemens, Eveline Pipolo Milan, et al. (+6)
9 [GO] 2024―Jan―02 An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants Ryuta Uraki, Masaki Imai, Mutsumi Ito, Seiya Yamayoshi, Maki Kiso, Nao Jounai, et al. (+4)
10 [GO] 2024―Jan―02 Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial Manon L. M. Prins, Geert V. T. Roozen, Cilia. R. Pothast, Wesley Huisman, Rob van Binnendijk, Gerco den Hartog, et al. (+18)
11 [GO] 2023―Nov―23 Ischemic stroke after COVID-19 bivalent vaccine administration in patients aged 65 years and older in the United States Maria P. Gorenflo, Pamela B. Davis, David C. Kaelber, Rong Xu
12 [GO] 2023―Nov―20 Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants Chon Phin Ong, Kaiming Tang, Pak-Hin Hinson Cheung, Hongzhuo Zhang, Tze-Tung Tang, Yaqian Xue, et al. (+5)
13 [GO] 2023―Nov―20 Outlook of pandemic preparedness in a post-COVID-19 world B. Adam Williams, Charles H. Jones, Verna Welch, Jane M. True
14 [GO] 2023―Oct―26 Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen Simon Doss-Gollin, Sanya Thomas, Byron Brook, Kimia Abedi, Célia Lebas, Floriane Auderset, et al. (+5)
15 [GO] 2023―Oct―25 Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants Nidhi Mittal, Sahil Kumar, Raju S. Rajmani, Randhir Singh, Céline Lemoine, Virginie Jakob, et al. (+11)
16 [GO] 2023―Oct―20 Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2 Henning Jacobsen, Ioannis Sitaras, Maeva Katzmarzyk, Viviana Cobos Jiménez, Robert Naughton, Melissa M. Higdon, Maria Deloria Knoll
17 [GO] 2023―Oct―20 A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity Awadalkareem Adam, Birte Kalveram, John Yun-Chung Chen, Jason Yeung, Leslie Rodriguez, Ankita Singh, et al. (+3)
18 [GO] 2023―Oct―11 Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability Lizhou Zhang, Kunal R. More, Amrita Ojha, Cody B. Jackson, Brian D. Quinlan, Hao Li, et al. (+4)
19 [GO] 2023―Oct―09 Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine Mingyuan Li, Lin Jia, Yanbo Xie, Wenlin Ma, Zhihong Yan, Fufeng Liu, et al. (+9)
20 [GO] 2023―Oct―05 COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition Shilin Zhao, Kris Y. W. Lok, Zhen Y. Sin, Ye Peng, Heidi S. L. Fan, Nitya Nagesh, et al. (+15)
21 [GO] 2023―Oct―04 Cross-protection and cross-neutralization capacity of ancestral and VOC-matched SARS-CoV-2 adenoviral vector-based vaccines Sabrina E. Vinzón, María V. Lopez, Eduardo G. A. Cafferata, Ariadna S. Soto, Paula M. Berguer, Luciana Vazquez, et al. (+20)
22 [GO] 2023―Sep―29 Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome Mariann Gyöngyösi, Dominika Lukovic, Julia Mester-Tonczar, Katrin Zlabinger, Patrick Einzinger, Andreas Spannbauer, et al. (+16)
23 [GO] 2023―Sep―29 Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2 Lorna Leal, Judit Pich, Laura Ferrer, Jocelyn Nava, Ruth Martí-Lluch, Ignasi Esteban, et al. (+75)
24 [GO] 2023―Sep―27 Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients Aram J. Krauson, Faye Victoria C. Casimero, Zakir Siddiquee, James R. Stone
25 [GO] 2023―Sep―14 Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELDTM and COVAXIN® induced immunity in COVID-19 exposed Indians Srabanti Rakshit, Sudhir Babji, Chaitra Parthiban, Ramya Madhavan, Vasista Adiga, Sharon Eveline J, et al. (+14)
26 [GO] 2023―Sep―01 Identifying a causal link between prolactin signaling pathways and COVID-19 vaccine-induced menstrual changes Rima Hajjo, Ensaf Momani, Dima A. Sabbah, Nancy Baker, Alexander Tropsha
27 [GO] 2023―Aug―12 Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells Robert G. E. Krause, Thandeka Moyo-Gwete, Simone I. Richardson, Zanele Makhado, Nelia P. Manamela, Tandile Hermanus, et al. (+19)
28 [GO] 2023―Aug―08 Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery Cuiping Liu, Lingshu Wang, Jonah S. Merriam, Wei Shi, Eun Sung Yang, Yi Zhang, et al. (+17)
29 [GO] 2023―Aug―04 Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants David N. Springer, Michael Bauer, Iris Medits, Jeremy V. Camp, Stephan W. Aberle, Clemens Burtscher, et al. (+4)
30 [GO] 2023―Jul―15 Maternal and neonatal outcomes of COVID-19 vaccination during pregnancy, a systematic review and meta-analysis Greg Marchand, Ahmed Taher Masoud, Sandeep Grover, Alexa King, Giovanna Brazil, Hollie Ulibarri, et al. (+10)
31 [GO] 2023―Jun―29 Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice Sonia Jangra, Jeffrey J. Landers, Gabriel Laghlali, Raveen Rathnasinghe, Prajakta Warang, Seok-Chan Park, et al. (+9)
32 [GO] 2023―Jun―09 Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination Patrick D. M. C. Katoto, Liliane N. Byamungu, Amanda S. Brand, Jacques L. Tamuzi, Mireille A. M. Kakubu, Charles S. Wiysonge, Glenda Gray
33 [GO] 2023―Jun―02 Antiviral effect of SARS-CoV-2 N-specific CD8+ T cells induced in lungs by engineered extracellular vesicles Francesco Manfredi, Chiara Chiozzini, Flavia Ferrantelli, Patrizia Leone, Katherina Pugliese, Massimo Spada, et al. (+7)
34 [GO] 2023―May―24 Developmental and reproductive toxicity of a recombinant protein subunit COVID-19 vaccine (ZF2001) in rats Yisheng Song, Jinjin Shao, Guangbiao She, Wanqiang Lv, Guoyu Chen, Jing Liu, et al. (+8)
35 [GO] 2023―May―17 Th1-dominant cytokine responses in kidney patients after COVID-19 vaccination are associated with poor humoral responses Yvette den Hartog, S. Reshwan K. Malahe, Wim J. R. Rietdijk, Marjolein Dieterich, Lennert Gommers, Daryl Geers, et al. (+15)
36 [GO] 2023―May―13 Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection Béré K. Diallo, Caitlín Ní Chasaide, Ting Y. Wong, Pauline Schmitt, Katherine S. Lee, Kelly Weaver, et al. (+5)
37 [GO] 2023―May―10 Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico Samuel Ponce-de-León, Martha Torres, Luis Enrique Soto-Ramírez, Juan José Calva, Patricio Santillán-Doherty, Dora Eugenia Carranza-Salazar, et al. (+27)
38 [GO] 2023―May―02 Risk assessment of retinal vascular occlusion after COVID-19 vaccination Jing-Xing Li, Yu-Hsun Wang, Henry Bair, Shu-Bai Hsu, Connie Chen, James Cheng-Chung Wei, Chun-Ju Lin
39 [GO] 2023―Apr―24 Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort Oliver Bürzle, Dominik Menges, Julian D. Maier, Daniel Schams, Milo A. Puhan, Jan Fehr, et al. (+2)
40 [GO] 2023―Apr―22 Resistance to COVID-19 vaccination and the social contract: evidence from Italy Sarah E. Kreps, Douglas L. Kriner
41 [GO] 2023―Apr―12 Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report Jane M. Knisely, Lucas E. Buyon, Rebecca Mandt, Rebecca Farkas, Shobana Balasingam, Karin Bok, et al. (+13)
42 [GO] 2023―Mar―27 Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice Catherine A. Cotter, Jeffrey L. Americo, Patricia L. Earl, Bernard Moss
43 [GO] 2023―Mar―26 SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies Shikha Shrivastava, Joshua M. Carmen, Zhongyan Lu, Shraddha Basu, Rajeshwer S. Sankhala, Wei-Hung Chen, et al. (+23)
44 [GO] 2023―Mar―26 PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application Zhihao Zhang, Jinhu Zhou, Peng Ni, Bing Hu, Normand Jolicoeur, Shuang Deng, et al. (+13)
45 [GO] 2023―Mar―16 Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants Felix Wussow, Mindy Kha, Taehyun Kim, Minh Ly, Marcal Yll-Pico, Swagata Kar, et al. (+3)
46 [GO] 2023―Mar―11 Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine David Benkeser, Youyi Fong, Holly E. Janes, Elizabeth J. Kelly, Ian Hirsch, Stephanie Sproule, et al. (+34)
47 [GO] 2023―Mar―06 Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination Yoshifumi Uwamino, Kengo Nagashima, Ayumi Yoshifuji, Shigeru Suga, Mizuho Nagao, Takao Fujisawa, et al. (+8)
48 [GO] 2023―Mar―03 Publisher Correction: Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice Etsuro Nanishi, Francesco Borriello, Hyuk-Soo Seo, Timothy R. O’Meara, Marisa E. McGrath, Yoshine Saito, et al. (+25)
49 [GO] 2023―Feb―25 Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination Hayley Holt, David A. Jolliffe, Mohammad Talaei, Sian Faustini, Giulia Vivaldi, Matthew Greenig, et al. (+8)
50 [GO] 2023―Feb―23 Independent control of COVID-19 vaccines by EU Official Control Authority Batch Release: challenges, strengths and successes Catherine Milne, Ralf Wagner, François Cano, Martijn Bruysters, Geneviève Waeterloos, Dieter Pullirsch, et al. (+2)
51 [GO] 2023―Feb―23 Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques Catherine Jacob-Dolan, Jingyou Yu, Katherine McMahan, Victoria Giffin, Abishek Chandrashekar, Amanda J. Martinot, et al. (+18)
52 [GO] 2023―Feb―14 Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice Etsuro Nanishi, Francesco Borriello, Hyuk-Soo Seo, Timothy R. O’Meara, Marisa E. McGrath, Yoshine Saito, et al. (+25)
53 [GO] 2023―Feb―13 Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19 Paulina Kaplonek, Deniz Cizmeci, Jessica Shih-Lu Lee, Sally A. Shin, Stephanie Fischinger, Philipe Gobeil, et al. (+4)
54 [GO] 2023―Feb―13 Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern Patrick O. Azevedo, Natália S. Hojo-Souza, Lídia P. Faustino, Marcílio J. Fumagalli, Isabella C. Hirako, Emiliano R. Oliveira, et al. (+11)
55 [GO] 2023―Feb―02 Is partisan conflict over COVID-19 vaccination eroding support for childhood vaccine mandates? Matt Motta
56 [GO] 2023―Feb―02 Author Correction: “World in motion” - emulsion adjuvants rising to meet the pandemic challenges Derek T. O’Hagan, Robbert van der Most, Rushit N. Lodaya, Margherita Coccia, Giuseppe Lofano
57 [GO] 2023―Jan―25 Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants Trung The Tran, Eline Benno Vaage, Adi Mehta, Adity Chopra, Lisa Tietze, Anette Kolderup, et al. (+34)
58 [GO] 2022―Dec―30 Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants Trung The Tran, Eline Benno Vaage, Adi Mehta, Adity Chopra, Lisa Tietze, Anette Kolderup, et al. (+34)
59 [GO] 2022―Dec―19 Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern Juan Shi, Gang Wang, Jian Zheng, Abhishek K. Verma, Xiaoqing Guan, Moffat M. Malisheni, et al. (+4)
60 [GO] 2022―Dec―19 Challenges and developments in universal vaccine design against SARS-CoV-2 variants Fangxin Zhao, Xiaodong Zai, Zhiling Zhang, Junjie Xu, Wei Chen
61 [GO] 2022―Dec―16 Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial Luke Tzu-Chi Liu, Cheng-Hsun Chiu, Nan-Chang Chiu, Boon-Fatt Tan, Chien-Yu Lin, Hao-Yuan Cheng, et al. (+4)
62 [GO] 2022―Dec―15 Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic Lei Huang, Francisco Tsz Tsun Lai, Vincent Ka Chun Yan, Franco Wing Tak Cheng, Ching Lung Cheung, Celine Sze Ling Chui, et al. (+7)
63 [GO] 2022―Dec―13 A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine Jenny G. Low, Ruklanthi de Alwis, Shiwei Chen, Shirin Kalimuddin, Yan Shan Leong, Tania Ken Lin Mah, et al. (+15)
64 [GO] 2022―Dec―03 BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children Yannic C. Bartsch, Jessica W. Chen, Jaewon Kang, Madeleine D. Burns, Kerri J. St Denis, Maegan L. Sheehan, et al. (+5)
65 [GO] 2022―Nov―28 Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccine Eugenia Z. Ong, Jia Xin Yee, Justin S. G. Ooi, Ayesa Syenina, Ruklanthi de Alwis, Shiwei Chen, et al. (+13)
66 [GO] 2022―Nov―24 Author Correction: A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability Emily A. Voigt, Alana Gerhardt, Derek Hanson, Madeleine F. Jennewein, Peter Battisti, Sierra Reed, et al. (+9)
67 [GO] 2022―Nov―15 Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant Ioannis Sitaras, Henning Jacobsen, Melissa M. Higdon, William E. Dowling, Naor Bar-Zeev, Maria Deloria Knoll
68 [GO] 2022―Nov―15 Impaired neutralizing antibodies and preserved cellular immunogenicity against SARS-CoV-2 in systemic autoimmune rheumatic diseases Porntip Intapiboon, Parichat Uae-areewongsa, Jomkwan Ongarj, Ratchanon Sophonmanee, Purilap Seepathomnarong, Bunya Seeyankem, et al. (+2)
69 [GO] 2022―Nov―15 Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination Maria G. Byazrova, Ekaterina A. Astakhova, Aygul R. Minnegalieva, Maria M. Sukhova, Artem A. Mikhailov, Alexey G. Prilipov, et al. (+2)
70 [GO] 2022―Nov―12 A potent, broadly protective vaccine against SARS-CoV-2 variants of concern Ziyan Wang, Jiao An, Kunpeng Liu, Pin Yu, Xin Fang, Jiadai Li, et al. (+20)
71 [GO] 2022―Nov―09 Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination Alessandra Buoninfante, Arno Andeweg, Alexander T. Baker, Mitesh Borad, Nigel Crawford, Jean-Michel Dogné, et al. (+13)
72 [GO] 2022―Nov―09 Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities Nathalie Charland, Philipe Gobeil, Stéphane Pillet, Iohann Boulay, Annie Séguin, Alexander Makarkov, et al. (+24)
73 [GO] 2022―Nov―02 A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability Emily A. Voigt, Alana Gerhardt, Derek Hanson, Madeleine F. Jennewein, Peter Battisti, Sierra Reed, et al. (+9)
74 [GO] 2022―Oct―28 Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates Lochana M. Seenappa, Aniela Jakubowski, Martin P. Steinbuck, Erica Palmer, Christopher M. Haqq, Crystal Carter, et al. (+4)
75 [GO] 2022―Oct―27 Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex Gabriel Dagotto, John D. Ventura, David R. Martinez, Tochi Anioke, Benjamin S. Chung, Mazuba Siamatu, et al. (+9)
76 [GO] 2022―Oct―21 Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection Kayla A. Holder, Danielle P. Ings, Debbie O. A. Harnum, Rodney S. Russell, Michael D. Grant
77 [GO] 2022―Oct―12 Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern Bassel Akache, Tyler M. Renner, Matthew Stuible, Nazanin Rohani, Yuneivy Cepero-Donates, Lise Deschatelets, et al. (+10)
78 [GO] 2022―Oct―01 Understanding change in COVID-19 vaccination intention with network analysis of longitudinal data from Dutch adults Monique Chambon, Wesley G. Kammeraad, Frenk van Harreveld, Jonas Dalege, Janneke E. Elberse, Han L. J. van der Maas
79 [GO] 2022―Sep―23 Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity Catherine Yankowski, Christoph Wirblich, Drishya Kurup, Matthias J. Schnell
80 [GO] 2022―Sep―06 Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population Nawamin Pinpathomrat, Porntip Intapiboon, Purilap Seepathomnarong, Jomkwan Ongarj, Ratchanon Sophonmanee, Jariya Hengprakop, et al. (+10)
81 [GO] 2022―Sep―02 SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates Reza Alimohammadi, Meysam Porgoo, Mohamad Eftekhary, Seyed Hossein Kiaie, Ehsan Ansari Dezfouli, Maryam Dehghani, et al. (+44)
82 [GO] 2022―Aug―19 Publisher Correction: An immunological autobiography: my year as a COVID-19 vaccine trial participant Ross M. Kedl
83 [GO] 2022―Aug―11 A Bayesian network analysis quantifying risks versus benefits of the Pfizer COVID-19 vaccine in Australia Jane E. Sinclair, Helen J. Mayfield, Kirsty R. Short, Samuel J. Brown, Rajesh Puranik, Kerrie Mengersen, et al. (+2)
84 [GO] 2022―Aug―02 Affordable SARS-CoV-2 protein vaccines for the pandemic endgame James A. Triccas, Joeri Kint, Florian M. Wurm
85 [GO] 2022―Jul―29 Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2 Mariana F. Tioni, Robert Jordan, Angie Silva Pena, Aditya Garg, Danlu Wu, Shannon I. Phan, et al. (+16)
86 [GO] 2022―Jul―26 Rational development of a combined mRNA vaccine against COVID-19 and influenza Qing Ye, Mei Wu, Chao Zhou, Xishan Lu, Baoying Huang, Ning Zhang, et al. (+14)
87 [GO] 2022―Jul―25 Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2 Adriano Taddeo, Inês Berenguer Veiga, Christelle Devisme, Renate Boss, Philippe Plattet, Sebastian Weigang, et al. (+4)
88 [GO] 2022―Jul―18 An immunological autobiography: my year as a COVID-19 vaccine trial participant Ross M. Kedl
89 [GO] 2022―Jul―06 Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S Dominique J. Barbeau, Judith M. Martin, Emily Carney, Emily Dougherty, Joshua D. Doyle, Terence S. Dermody, et al. (+6)
90 [GO] 2022―Jun―28 Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2 Hong-Su Park, Yumiko Matsuoka, Cindy Luongo, Lijuan Yang, Celia Santos, Xueqiao Liu, et al. (+12)
91 [GO] 2022―Jun―03 A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection Tsai-Teng Tzeng, Kit Man Chai, Kuan-Yin Shen, Chia-Yi Yu, Shiu-Ju Yang, Wan-Chun Huang, et al. (+6)
92 [GO] 2022―May―26 Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease Bennett J. Davenport, Alexis Catala, Stuart M. Weston, Robert M. Johnson, Jeremy Ardanuy, Holly L. Hammond, et al. (+4)
93 [GO] 2022―May―25 Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism Martin F. Bachmann, Mona O. Mohsen, Daniel E. Speiser
94 [GO] 2022―May―23 Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice Lilit Grigoryan, Audrey Lee, Alexandra C. Walls, Lilin Lai, Benjamin Franco, Prabhu S. Arunachalam, et al. (+24)
95 [GO] 2022―May―13 Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population Nawamin Pinpathomrat, Porntip Intapiboon, Purilap Seepathomnarong, Jomkwan Ongarj, Ratchanon Sophonmanee, Jariya Hengprakop, et al. (+10)
96 [GO] 2022―Apr―26 Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters George Giorgi Babuadze, Hugues Fausther-Bovendo, Marc-Antoine deLaVega, Brandon Lillie, Maedeh Naghibosadat, Nariman Shahhosseini, et al. (+16)
97 [GO] 2022―Apr―25 A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2 Philipp A. Ilinykh, Sivakumar Periasamy, Kai Huang, Natalia A. Kuzmina, Palaniappan Ramanathan, Michelle N. Meyer, et al. (+9)
98 [GO] 2022―Apr―08 BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, et al. (+9)
99 [GO] 2022―Mar―14 Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge Ting Y. Wong, Katherine S. Lee, Brynnan P. Russ, Alexander M. Horspool, Jason Kang, Michael T. Winters, et al. (+15)
100 [GO] 2022―Mar―08 Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant Kevin K. Ariën, Leo Heyndrickx, Johan Michiels, Katleen Vereecken, Kurt Van Lent, Sandra Coppens, et al. (+8)
101 [GO] 2022―Mar―02 Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination Eng Eong Ooi, Arti Dhar, Richard Petruschke, Camille Locht, Philippe Buchy, Jenny Guek Hong Low
102 [GO] 2022―Mar―02 Pandemic-response adenoviral vector and RNA vaccine manufacturing Zoltán Kis, Kyungjae Tak, Dauda Ibrahim, Maria M. Papathanasiou, Benoît Chachuat, Nilay Shah, Cleo Kontoravdi
103 [GO] 2022―Feb―28 Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy Zabrina L. Brumme, Francis Mwimanzi, Hope R. Lapointe, Peter K. Cheung, Yurou Sang, Maggie C. Duncan, et al. (+37)
104 [GO] 2022―Feb―23 An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission Kairat Tabynov, Nurkeldi Turebekov, Meruert Babayeva, Gleb Fomin, Toktassyn Yerubayev, Tlektes Yespolov, et al. (+4)
105 [GO] 2022―Feb―18 Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines Michael Karbiener, Maria R. Farcet, Andreas Zollner, Taisei Masuda, Mitsuhiro Mori, Alexander R. Moschen, Thomas R. Kreil
106 [GO] 2022―Feb―09 Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice Adrián Lázaro-Frías, Patricia Pérez, Carmen Zamora, Pedro J. Sánchez-Cordón, María Guzmán, Joanna Luczkowiak, et al. (+4)
107 [GO] 2022―Feb―08 Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination Yusuke Miyashita, Takanobu Yoshida, Yuriko Takagi, Hirotake Tsukamoto, Ken Takashima, Takahisa Kouwaki, et al. (+4)
108 [GO] 2022―Jan―21 Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates Flavia Chiuppesi, Vu H. Nguyen, Yoonsuh Park, Heidi Contreras, Veronica Karpinski, Katelyn Faircloth, et al. (+15)
109 [GO] 2022―Jan―10 Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters Lisa H. Tostanoski, Abishek Chandrashekar, Shivani Patel, Jingyou Yu, Catherine Jacob-Dolan, Aiquan Chang, et al. (+29)
110 [GO] 2021―Dec―21 “World in motion” - emulsion adjuvants rising to meet the pandemic challenges Derek T. O’Hagan, Robbert van der Most, Rushit N. Lodaya, Margherita Coccia, Giuseppe Lofano
111 [GO] 2021―Dec―20 Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2 Ria Lassaunière, Charlotta Polacek, Gregers J. Gram, Anders Frische, Jeanette Linnea Tingstedt, Maren Krüger, et al. (+11)
112 [GO] 2021―Dec―16 Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza Sudha Chivukula, Timothy Plitnik, Timothy Tibbitts, Shrirang Karve, Anusha Dias, Donghui Zhang, et al. (+24)
113 [GO] 2021―Dec―13 SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses Joshua M. Carmen, Shikha Shrivastava, Zhongyan Lu, Alexander Anderson, Elaine B. Morrison, Rajeshwer S. Sankhala, et al. (+11)
114 [GO] 2021―Dec―03 MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge Clement A. Meseda, Charles B. Stauft, Prabhuanand Selvaraj, Christopher Z. Lien, Cyntia Pedro, Ivette A. Nuñez, et al. (+3)
115 [GO] 2021―Dec―03 A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern Mitch Brinkkemper, Philip J. M. Brouwer, Pauline Maisonnasse, Marloes Grobben, Tom G. Caniels, Meliawati Poniman, et al. (+11)
116 [GO] 2021―Nov―30 A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection Claudio Counoupas, Matt D. Johansen, Alberto O. Stella, Duc H. Nguyen, Angela L. Ferguson, Anupriya Aggarwal, et al. (+18)
117 [GO] 2021―Nov―29 Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies Chaojie Zhong, Hongjie Xia, Awadalkareem Adam, Binbin Wang, Renee L. Hajnik, Yuejin Liang, et al. (+10)
118 [GO] 2021―Nov―29 Immune response against SARS-CoV-2 variants: the role of neutralization assays Alicja Maria Chmielewska, Anna Czarnota, Krystyna Bieńkowska-Szewczyk, Katarzyna Grzyb
119 [GO] 2021―Nov―18 Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant Mayuresh M. Abhyankar, Barbara J. Mann, Jeffrey M. Sturek, Savannah Brovero, G. Brett Moreau, Anjali Sengar, et al. (+7)
120 [GO] 2021―Nov―04 Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination Rafael Assis, Aarti Jain, Rie Nakajima, Algis Jasinskas, Saahir Khan, Anton Palma, et al. (+22)
121 [GO] 2021―Oct―28 Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 Harry Kleanthous, Judith Maxwell Silverman, Karen W. Makar, In-Kyu Yoon, Nicholas Jackson, David W. Vaughn
122 [GO] 2021―Oct―28 A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge Kathryn McGuckin Wuertz, Erica K. Barkei, Wei-Hung Chen, Elizabeth J. Martinez, Ines Lakhal-Naouar, Linda L. Jagodzinski, et al. (+50)
123 [GO] 2021―Oct―25 Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore Bei Wang, Yun Shan Goh, Tessa Prince, Eve Zi Xian Ngoh, Siti Nazihah Mohd Salleh, Pei Xiang Hor, et al. (+12)
124 [GO] 2021―Oct―20 An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2 between cats Martijn A. Langereis, Irina C. Albulescu, Judith Stammen-Vogelzangs, Morindy Lambregts, Ken Stachura, Suzan Miller, et al. (+13)
125 [GO] 2021―Oct―14 INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants Viviane M. Andrade, Aaron Christensen-Quick, Joseph Agnes, Jared Tur, Charles Reed, Richa Kalia, et al. (+18)
126 [GO] 2021―Sep―30 The shot, the message, and the messenger: COVID-19 vaccine acceptance in Latin America Pablo Argote, Elena Barham, Sarah Zukerman Daly, Julian E. Gerez, John Marshall, Oscar Pocasangre
127 [GO] 2021―Aug―24 Neutralization of MERS coronavirus through a scalable nanoparticle vaccine Mona O. Mohsen, Dominik Rothen, Ina Balke, Byron Martina, Vilija Zeltina, Varghese Inchakalody, et al. (+7)
128 [GO] 2021―Aug―16 Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action Franz X. Heinz, Karin Stiasny
129 [GO] 2021―Aug―12 National control laboratory independent lot testing of COVID-19 vaccines: the UK experience Nicola J. Rose, Paul Stickings, Silke Schepelmann, Marc J. A. Bailey, Chris Burns
130 [GO] 2021―Aug―11 Benefit of COVID-19 vaccination accounting for potential risk compensation John P. A. Ioannidis
131 [GO] 2021―Aug―05 Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic Samir Andrade Mendonça, Reka Lorincz, Paul Boucher, David T. Curiel
132 [GO] 2021―Jul―22 A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19 Delphine C. Malherbe, Drishya Kurup, Christoph Wirblich, Adam J. Ronk, Chad Mire, Natalia Kuzmina, et al. (+7)
133 [GO] 2021―Jun―17 A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells Simon G. P. Funnell, Babak Afrough, John James Baczenas, Neil Berry, Kevin R. Bewley, Rebecca Bradford, et al. (+11)
134 [GO] 2021―May―14 Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation Sarah Kreps, Nabarun Dasgupta, John S. Brownstein, Yulin Hswen, Douglas L. Kriner
135 [GO] 2021―May―13 Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation Lauren M. Meyers, Andres H. Gutiérrez, Christine M. Boyle, Frances Terry, Bethany G. McGonnigal, Andres Salazar, et al. (+4)
136 [GO] 2021―May―13 Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 Ian McDonald, Sam M. Murray, Catherine J. Reynolds, Daniel M. Altmann, Rosemary J. Boyton
137 [GO] 2021―May―10 ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets Glenn A. Marsh, Alexander J. McAuley, Gough G. Au, Sarah Riddell, Daniel Layton, Nagendrakumar B. Singanallur, et al. (+38)
138 [GO] 2021―Apr―22 Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine Natalie Thiel, Casey Selwyn, Georgina Murphy, Shmona Simpson, Ajoy C. Chakrabarti
139 [GO] 2021―Apr―21 Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases Velayudhan Mohan Kumar, Seithikurippu R. Pandi-Perumal, Ilya Trakht, Sadras Panchatcharam Thyagarajan
140 [GO] 2021―Apr―19 Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models Kirill V. Kalnin, Timothy Plitnik, Michael Kishko, Jinrong Zhang, Donghui Zhang, Adrien Beauvais, et al. (+32)
141 [GO] 2021―Apr―16 mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents Susanne Rauch, Nicole Roth, Kim Schwendt, Mariola Fotin-Mleczek, Stefan O. Mueller, Benjamin Petsch
142 [GO] 2021―Apr―14 Access to and equitable distribution of COVID-19 vaccine in low-income countries Krishna Prasad Acharya, Tirth Raj Ghimire, Supram Hosuru Subramanya
143 [GO] 2021―Apr―13 Considerations for bioanalytical characterization and batch release of COVID-19 vaccines Gautam Sanyal, Anna Särnefält, Arun Kumar
144 [GO] 2021―Mar―30 Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters Qingmei Jia, Helle Bielefeldt-Ohmann, Rachel M. Maison, Saša Masleša-Galić, Sarah K. Cooper, Richard A. Bowen, Marcus A. Horwitz
145 [GO] 2021―Mar―25 The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization Jing Zou, Xuping Xie, Camila R. Fontes-Garfias, Kena A. Swanson, Isis Kanevsky, Kristin Tompkins, et al. (+4)
146 [GO] 2021―Mar―19 Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease Joan E. M. van der Lubbe, Sietske K. Rosendahl Huber, Aneesh Vijayan, Liesbeth Dekking, Ella van Huizen, Jessica Vreugdenhil, et al. (+21)
147 [GO] 2021―Mar―19 Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 Hansam Cho, Yuyeon Jang, Ki-Hoon Park, Hanul Choi, Aleksandra Nowakowska, Hee-Jung Lee, et al. (+6)
148 [GO] 2021―Feb―22 SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates Nikolaos C. Kyriakidis, Andrés López-Cortés, Eduardo Vásconez González, Alejandra Barreto Grimaldos, Esteban Ortiz Prado
149 [GO] 2021―Feb―11 Promoting versatile vaccine development for emerging pandemics Joshua T. Monrad, Jonas B. Sandbrink, Neil G. Cherian
150 [GO] 2021―Jan―25 Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters Rebecca L. Brocato, Steven A. Kwilas, Robert K. Kim, Xiankun Zeng, Lucia M. Principe, Jeffrey M. Smith, Jay W. Hooper
151 [GO] 2021―Jan―04 SARS-CoV-2 structural features may explain limited neutralizing-antibody responses Martin F. Bachmann, Mona O. Mohsen, Lisha Zha, Monique Vogel, Daniel E. Speiser
152 [GO] 2020―Nov―03 Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections Jay Epstein, W. Martin Smid, Silvano Wendel, Daniel Somuah, Thierry Burnouf
153 [GO] 2020―Oct―23 Navigating facilitated regulatory pathways during a disease X pandemic Shmona Simpson, Ajoy Chakrabarti, David Robinson, Keith Chirgwin, Murray Lumpkin
154 [GO] 2020―Oct―16 Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2 Drishya Kurup, Christoph Wirblich, Holly Ramage, Matthias J. Schnell
155 [GO] 2020―Oct―08 Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein Alexander J. McAuley, Michael J. Kuiper, Peter A. Durr, Matthew P. Bruce, Jennifer Barr, Shawn Todd, et al. (+14)
156 [GO] 2020―Sep―28 Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses Rinke Bos, Lucy Rutten, Joan E. M. van der Lubbe, Mark J. G. Bakkers, Gijs Hardenberg, Frank Wegmann, et al. (+18)
157 [GO] 2020―Sep―04 Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein René Wintjens, Amanda Makha Bifani, Pablo Bifani
158 [GO] 2020―Jul―27 Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 Simon P. Graham, Rebecca K. McLean, Alexandra J. Spencer, Sandra Belij-Rammerstorfer, Daniel Wright, Marta Ulaszewska, et al. (+36)
159 [GO] 2020―Jul―06 Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic Leonardo M. R. Ferreira, Mohammed A. Mostajo-Radji
160 [GO] 2020―Jun―15 Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens Jayanthi Wolf, Samantha Bruno, Michael Eichberg, Risat Jannat, Sharon Rudo, Susan VanRheenen, Beth-Ann Coller
161 [GO] 2020―May―28 Universal coronavirus vaccines: the time to start is now Luca T. Giurgea, Alison Han, Matthew J. Memoli
162 [GO] 2020―May―25 Certainty of success: three critical parameters in coronavirus vaccine development David C. Kaslow
163 [GO] 2020―Apr―30 COVID-19 vaccines: breaking record times to first-in-human trials Young Chan Kim, Barbara Dema, Arturo Reyes-Sandoval
164 [GO] 2020―Mar―06 The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines Weilong Shang, Yi Yang, Yifan Rao, Xiancai Rao
165 [GO] 2019―Dec―06 Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts Raffael Nachbagauer, Bruno Salaun, Daniel Stadlbauer, Mohammad A. Behzadi, Damien Friel, Arvind Rajabhathor, et al. (+11)

165 Results       Page 1


Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.008 sec